Yes, patients with coronary artery occlusion can safely take Farxiga (dapagliflozin)
Farxiga is not only safe but strongly recommended for patients with coronary artery disease, including those with vessel occlusion, particularly when they have heart failure, chronic kidney disease, or type 2 diabetes. The evidence demonstrates significant cardiovascular benefits including reduced mortality and hospitalization rates in this population.
Evidence-Based Recommendations
For Patients with Atherosclerotic Cardiovascular Disease
The 2021 CCS/CHFS guidelines provide a Strong Recommendation with High-Quality Evidence that SGLT2 inhibitors like dapagliflozin should be used in patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce the risk of heart failure hospitalization and death 1. This explicitly includes patients with coronary artery occlusion.
For Patients with Heart Failure
If the patient with coronary occlusion has developed heart failure (reduced or preserved ejection fraction), dapagliflozin carries an even stronger indication. The guidelines recommend SGLT2 inhibitors to improve symptoms, quality of life, and reduce cardiovascular mortality and heart failure hospitalization, regardless of diabetes status 1, 2.
For Patients with Chronic Kidney Disease
The 2022 ADA/KDIGO consensus recommends SGLT2 inhibitors for patients with CKD and eGFR ≥20 mL/min/1.73 m² to reduce cardiovascular death and heart failure hospitalization 3. This applies to patients with coronary disease and kidney involvement.
Clinical Evidence Supporting Safety and Efficacy
Recent research specifically demonstrates benefits in coronary artery disease:
- Enhanced coronary collateral circulation: Dapagliflozin use was associated with significantly better coronary collateral development in patients with total coronary occlusion (odds ratio: 32.5) 4
- Post-PCI outcomes: In patients undergoing percutaneous coronary intervention for acute myocardial infarction, dapagliflozin improved left ventricular function, reduced adverse remodeling, and decreased major adverse cardiovascular events 5, 6, 7
- Improved vascular function: Dapagliflozin enhanced vascular endothelial function and reduced cardiovascular events in diabetic patients with coronary artery disease 8
Key Safety Considerations and Monitoring
Renal Function Requirements
- Safe to initiate if eGFR ≥25 mL/min/1.73 m² for cardiovascular indications 3, 9
- Can continue even if eGFR falls below 25 mL/min/1.73 m² once already on therapy 9
- For glycemic control specifically, requires eGFR ≥45 mL/min/1.73 m² 9
Volume Status Assessment
Before starting dapagliflozin, assess and correct volume depletion 9. This is particularly important in patients who may be on multiple diuretics post-MI or for heart failure. Consider proactive diuretic dose reduction in high-risk patients 3, 10.
Perioperative Management
Withhold dapagliflozin for at least 3 days before major surgery or procedures with prolonged fasting to reduce ketoacidosis risk 9. Resume when clinically stable and oral intake restored.
Common Pitfalls to Avoid
Don't stop for temporary eGFR dip: Expect a reversible 3-5 mL/min/1.73 m² decline in eGFR within the first 4 weeks—this is hemodynamic and does not require discontinuation 3, 10
Implement sick day rules: Hold dapagliflozin during acute illness with nausea, vomiting, or diarrhea to prevent volume depletion and ketoacidosis 3, 10, 9
Monitor for genital mycotic infections: Counsel on hygiene; women have 10-15% risk 1. These typically respond to antifungals without requiring drug discontinuation
Adjust insulin/sulfonylureas: Reduce doses to prevent hypoglycemia when initiating dapagliflozin in diabetic patients 3, 10
Contraindications (None Related to Coronary Disease)
The only absolute contraindication is hypersensitivity to dapagliflozin 9. Coronary artery occlusion is not a contraindication. Type 1 diabetes is also contraindicated for SGLT2 inhibitors 1.
Dosing
- Standard dose: 10 mg once daily for cardiovascular and renal protection 9
- For glycemic control: May start at 5 mg and increase to 10 mg if needed 9
- Take with or without food 9
Bottom Line Algorithm
Start dapagliflozin 10 mg daily if:
- Coronary artery disease (including occlusion) present, AND
- eGFR ≥25 mL/min/1.73 m², AND
- No volume depletion (correct first if present), AND
- Not type 1 diabetes, AND
- No hypersensitivity to drug
The presence of coronary artery occlusion is actually an indication for, not against, dapagliflozin therapy given the demonstrated cardiovascular mortality benefits and potential enhancement of collateral circulation 1, 4.